Skip to main content
Biosimilars
Bioequivalence of Bevacizumab Reference and Its Biosimilar BCD-021 in Nonsquamous NSCLC
Read More
Biosimilars
Five-Year Follow-Up of a Comparative Phase 3 Study of SB3 and Trastuzumab Reference in HER2-Positive Early or Locally Advanced Breast Cancer
Read More
Biosimilars
Comparative Analysis of Safety, Efficacy, and Immunogenicity of Trastuzumab Reference and Its Biosimilar TX05 in HER2-Positive Early Breast Cancer
Read More
Biosimilars
Oncologists’ Knowledge and Perspectives on the Use of Biosimilars
Read More
Biosimilars
A Successful Model of Biosimilar Adoption in a Community Oncology Practice
Read More
Biosimilars
Real-World Trends in Biosimilar Prescribing Among Oncology Providers
Read More
Biosimilars
Real-World Utilization and Cost Patterns with Biosimilar and Filgrastim Reference in a Community Oncology Setting
Read More
Biosimilars
Real-World Evidence of Bevacizumab-awwb Use in a Population of Patients with Cancer
Read More
Biosimilars
Same-Day Pegfilgrastim-cbqv Administration Is Feasible in Patients with Breast Cancer Receiving Myelosuppressive Chemotherapy Regimens
Read More
Biosimilars
Real-World Evidence of Cardiac Safety of Trastuzumab Biosimilar Trastuzumab-anns in Breast Cancer
Read More
Page 73 of 199
Results 721 - 730 of 1986